Controlled release formulation of divalproex sodium

Abstract From the Canadian patent

A new oral polymeric controlled release formulation suitable for the once-a-day administration of valproate compounds such as divalproex, sodium, has been discovered. This formulation exhibits significant advantages over the sustained release valproate formulations of the prior art. This formulation minimizes the variation between peak and trough plasma levels of valproate over a 24 hour dosing period. This formulation follows a zero-order release pattern thus producing essentially flat plasma levels of valproate once, steady-state levels have been achieved. This results in a significantly lower incidence of side effects for patients consuming such a formulation.